Motilal Oswal Keeps Neutral Rating on Dr Reddy’s, Sets Rs 1,180 Target
Motilal Oswal says Dr Reddy’s Laboratories’ 2QFY27 revenue was in line, while EBITDA and PAT were 30% ahead of its estimates after adjusting for one-time income.
Motilal Oswal says Dr Reddy’s Laboratories’ 2QFY27 revenue was in line, while EBITDA and PAT were 30% ahead of its estimates after adjusting for one-time income.